- Home
- ALGS vs SLGL Comparison
ALGS vs SLGL Comparison
Compare ALGS & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALGS
- SLGL
- Stock Information
- Founded
- ALGS 2018
- SLGL 1997
- Country
- ALGS United States
- SLGL Israel
- Employees
- ALGS N/A
- SLGL N/A
- Industry
- ALGS Biotechnology: Pharmaceutical Preparations
- SLGL Biotechnology: Pharmaceutical Preparations
- Sector
- ALGS Health Care
- SLGL Health Care
- Exchange
- ALGS Nasdaq
- SLGL Nasdaq
- Market Cap
- ALGS 64.8M
- SLGL 69.1M
- IPO Year
- ALGS 2020
- SLGL 2018
- Fundamental
- Price
- ALGS $7.21
- SLGL $33.50
- Analyst Decision
- ALGS Strong Buy
- SLGL Strong Buy
- Analyst Count
- ALGS 2
- SLGL 1
- Target Price
- ALGS $60.00
- SLGL $50.00
- AVG Volume (30 Days)
- ALGS 99.6K
- SLGL 11.6K
- Earning Date
- ALGS 11-06-2025
- SLGL 11-07-2025
- Dividend Yield
- ALGS N/A
- SLGL N/A
- EPS Growth
- ALGS N/A
- SLGL N/A
- EPS
- ALGS N/A
- SLGL N/A
- Revenue
- ALGS $3,174,000.00
- SLGL $23,931,000.00
- Revenue This Year
- ALGS N/A
- SLGL N/A
- Revenue Next Year
- ALGS N/A
- SLGL N/A
- P/E Ratio
- ALGS N/A
- SLGL N/A
- Revenue Growth
- ALGS N/A
- SLGL 264.86
- 52 Week Low
- ALGS $3.76
- SLGL $4.01
- 52 Week High
- ALGS $46.80
- SLGL $52.26
- Technical
- Relative Strength Index (RSI)
- ALGS 28.33
- SLGL 43.78
- Support Level
- ALGS $9.25
- SLGL $34.50
- Resistance Level
- ALGS $8.76
- SLGL $39.00
- Average True Range (ATR)
- ALGS 0.77
- SLGL 3.34
- MACD
- ALGS -0.30
- SLGL -1.26
- Stochastic Oscillator
- ALGS 2.68
- SLGL 20.90
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.